Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eventide Healthcare & Life Sciences Fund Class A Shares (ETAHX)

19.86
Net Asset Value
+1.07%
1 Day
-16.41%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
5.75
Sales Expenses
1.57%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It is non-diversified.

Performance

1 month-0.56% 3 years+11.40%
3 months+1.34% 5 years--
1 year-12.10% Since inception+21.85%
Data through --

Peer Comparisonvs. Health

 ETAHXCategory
Performance 5-yr return--+15.57%
Expense ratio1.57%1.32%
Risk 5 year sharpe ratio--1.15
Net assets$301.5M$3.3B
Average market cap$1.4B$31.2B
Average P/E--18.7
Portfolio turnover26%26%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyEventide Funds
Fund manager & tenureFinny Kuruvilla / 3 Years
Minimal initial investment$1,000.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock86.04%
International stock5.89%
Cash4.96%
Fixed income1.63%
Other1.48%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
FPRX Five Prime Therapeutics Inc4.60%
LOXO Loxo Oncology Inc3.64%
COLL Collegium Pharmaceutical Inc3.52%
SUPN Supernus Pharmaceuticals Inc2.92%
DBVT DBV Technologies SA2.71%
TSRO TESARO Inc2.64%
CELG Celgene2.51%
ATHN athenahealth Inc2.37%
SGEN Seattle Genetics Inc2.28%
KITE Kite Pharma Inc2.27%

Partner Offers